and Expansion of CD33/HBG Promoter-edited HSPCs with Mylotarg

Overview

Journal Mol Ther Methods Clin Dev

Publisher Cell Press

Date 2024 Oct 21

PMID 39429723

Authors

Aphrodite Georgakopoulou

Chang Li

Hans-Peter Kiem

Andre Lieber

Affiliations

Soon will be listed here.

Abstract

We developed an HSC gene therapy approach that consists of HSC mobilization and intravenous injection of HSC-tropic HDAd vectors. To achieve therapeutically relevant numbers of corrected cells, we incorporated expansion of transduced cells. We used an HDAd vector for a multiplex adenine base editing approach to (1) remove the region within CD33 that is recognized by gemtuzumab ozogamicin (GO) (Mylotarg), and (2) create therapeutic edits within the HBG1/2 promoters to reactivate γ-globin/HbF. studies with HDAd-transduced human CD34 cells showed editing of both targeted sites and a 2- to 3-fold GO-mediated expansion of edited erythroid/myeloid progenitors. After erythroid differentiation, up to 40% of erythrocytes were HbF positive. For studies, mice were transplanted with human CD34 cells. After engraftment, HSCs were mobilized with G-CSF/AMD3100 followed by an intravenous HDAd injection and GO-mediated selection. Two months later, editing in human cells within the bone marrow was significantly higher in GO-treated mice. The percentage of HbF human erythroid cells was 2.5-fold greater compared with untreated mice. These data indicate that GO selection can increase edited erythroid cells.

References

Wang H, Germond A, Li C, Gil S, Kim J, Kiem H . In vivo HSC transduction in rhesus macaques with an HDAd5/3+ vector targeting desmoglein 2 and transiently overexpressing cxcr4. Blood Adv. 2022; 6(15):4360-4372. PMC: 9636333. DOI: 10.1182/bloodadvances.2022007975. View

Psatha N, Sgouramali E, Gkountis A, Siametis A, Baliakas P, Constantinou V . Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model. Hum Gene Ther Methods. 2014; 25(6):317-27. PMC: 4268579. DOI: 10.1089/hgtb.2014.005. View

Brashem-Stein C, Flowers D, Smith F, Staats S, Andrews R, Bernstein I . Ontogeny of hematopoietic stem cell development: reciprocal expression of CD33 and a novel molecule by maturing myeloid and erythroid progenitors. Blood. 1993; 82(3):792-9. View

Psatha N, Georgakopoulou A, Li C, Nandakumar V, Georgolopoulos G, Acosta R . Enhanced HbF reactivation by multiplex mutagenesis of thalassemic CD34+ cells in vitro and in vivo. Blood. 2021; 138(17):1540-1553. PMC: 8554647. DOI: 10.1182/blood.2020010020. View

Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M . Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002; 118(4):560-6. DOI: 10.1309/1WMW-CMXX-4WN4-T55U. View

Humbert O, Laszlo G, Sichel S, Ironside C, Haworth K, Bates O . Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Leukemia. 2018; 33(3):762-808. DOI: 10.1038/s41375-018-0277-8. View

Wang H, Georgakopoulou A, Psatha N, Li C, Capsali C, Samal H . In vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia. J Clin Invest. 2018; 129(2):598-615. PMC: 6355219. DOI: 10.1172/JCI122836. View

Bouchez L, Boitano A, de Lichtervelde L, Romeo R, Cooke M, Schultz P . Small-molecule regulators of human stem cell self-renewal. Chembiochem. 2011; 12(6):854-7. DOI: 10.1002/cbic.201000734. View

Fitzhugh C, Cordes S, Taylor T, Coles W, Roskom K, Link M . At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood. 2017; 130(17):1946-1948. PMC: 5659067. DOI: 10.1182/blood-2017-03-772392. View

10.

Li C, Georgakopoulou A, Newby G, Everette K, Nizamis E, Paschoudi K . In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies. JCI Insight. 2022; 7(19). PMC: 9675455. DOI: 10.1172/jci.insight.162939. View

11.

Li C, Anderson A, Wang H, Gil S, Kim J, Huang L . Stable HIV decoy receptor expression after in vivo HSC transduction in mice and NHPs: Safety and efficacy in protection from SHIV. Mol Ther. 2023; 31(4):1059-1073. PMC: 10124088. DOI: 10.1016/j.ymthe.2023.02.002. View

12.

Psatha N, Georgolopoulos G, Phelps S, Papayannopoulou T . Brief Report: A Differential Transcriptomic Profile of Ex Vivo Expanded Adult Human Hematopoietic Stem Cells Empowers Them for Engraftment Better than Their Surface Phenotype. Stem Cells Transl Med. 2017; 6(10):1852-1858. PMC: 6430062. DOI: 10.1002/sctm.17-0048. View

13.

Petty N, Radtke S, Fields E, Humbert O, Llewellyn M, Laszlo G . Efficient long-term multilineage engraftment of CD33-edited hematopoietic stem/progenitor cells in nonhuman primates. Mol Ther Methods Clin Dev. 2023; 31:101121. PMC: 10585325. DOI: 10.1016/j.omtm.2023.101121. View

14.

Li C, Georgakopoulou A, Newby G, Chen P, Everette K, Paschoudi K . In vivo HSC prime editing rescues sickle cell disease in a mouse model. Blood. 2023; 141(17):2085-2099. PMC: 10163316. DOI: 10.1182/blood.2022018252. View

15.

Douay L, Giarratana M . Ex vivo generation of human red blood cells: a new advance in stem cell engineering. Methods Mol Biol. 2008; 482:127-40. DOI: 10.1007/978-1-59745-060-7_8. View

16.

Boitano A, Wang J, Romeo R, Bouchez L, Parker A, Sutton S . Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010; 329(5997):1345-8. PMC: 3033342. DOI: 10.1126/science.1191536. View

17.

Li C, Georgakopoulou A, Mishra A, Gil S, Hawkins R, Yannaki E . In vivo HSPC gene therapy with base editors allows for efficient reactivation of fetal γ-globin in β-YAC mice. Blood Adv. 2021; 5(4):1122-1135. PMC: 7903237. DOI: 10.1182/bloodadvances.2020003702. View

18.

Hunt J, Samson C, du Rand A, Sheppard H . Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells. Hum Genet. 2023; 142(6):705-720. PMC: 10182114. DOI: 10.1007/s00439-023-02561-1. View

19.

Ellery P, Tippett E, Chiu Y, Paukovics G, Cameron P, Solomon A . The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol. 2007; 178(10):6581-9. DOI: 10.4049/jimmunol.178.10.6581. View

20.

Wang H, Georgakopoulou A, Li C, Liu Z, Gil S, Bashyam A . Curative in vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements. JCI Insight. 2020; 5(16). PMC: 7455141. DOI: 10.1172/jci.insight.139538. View